In this context, the IRE1α/Caspase-2-S1P signaling branch has been implicated in SREBP-1 activation and may exacerbate the “lipotoxicity–inflammation” feedback loop, highlighting its potential as a therapeutic target in MASLD [6, 7]. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.